8-K: Citius Oncology's LYMPHIR Receives Permanent J-Code from CMS, Streamlining Reimbursement

Citius Oncology and Citius Pharmaceuticals announce that LYMPHIR has been assigned a unique, permanent J-code by the Centers for Medicare & Medicaid Services, effective April 1, 2025, to streamline billing and reimbursement.

Summary

• Citius Pharmaceuticals and its subsidiary, Citius Oncology, announced that LYMPHIR (denileukin diftitox-cxdl) has been assigned a permanent J-code (J9161) by the Centers for Medicare & Medicaid Services (CMS).
• The J-code will be effective April 1, 2025.
• This code is expected to streamline the billing and reimbursement process for LYMPHIR.
• LYMPHIR is approved by the FDA for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
• Management estimates the initial market for LYMPHIR currently exceeds $400 million.
• LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the J-code assignment, which is a crucial step for commercialization. However, the presence of safety warnings and the need for additional funding temper the overall outlook.

Positives

• The assignment of a permanent J-code is a critical milestone in supporting patient access to LYMPHIR.
• The J-code provides coding clarity for physicians and facilities administering LYMPHIR.
• The J-code facilitates reimbursement from commercial and government insurance (VA, DoD, Medicare) coverage.
• LYMPHIR has FDA approval for a specific indication, providing a treatment option for patients with CTCL.
• Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies.

Negatives

• LYMPHIR carries a boxed warning for Capillary Leak Syndrome (CLS), which can be life-threatening or fatal.
• Clinical trials showed a 27% incidence of CLS in patients, with one fatal occurrence.
• LYMPHIR can cause serious visual impairment, with a 9% incidence in clinical trials.
• Infusion-related reactions were reported in 69% of patients in clinical trials.
• LYMPHIR can cause hepatotoxicity, with elevated ALT and AST levels reported in clinical trials.
• Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman.

Risks

• The commercialization of LYMPHIR depends on Citius' ability to procure cGMP commercial-scale supply.
• The company's success depends on obtaining and maintaining financing and strategic agreements.
• There are risks associated with preclinical and clinical testing.
• The company faces competition in the market.
• The company's success depends on the acceptance of LYMPHIR by the market.
• The company's success depends on the ability of LYMPHIR to impact the quality of life of its target patient populations.

Future Outlook

The company anticipates that the permanent J-code will support patient access to LYMPHIR and facilitate reimbursement, contributing to the commercial success of the product.

Management Comments

• Leonard Mazur, Chairman and CEO of Citius Pharma and Citius Oncology, stated that the establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement.
• Leonard Mazur stated that this achievement is a key step in ensuring that LYMPHIR is accessible to patients with commercial and government insurance (VA, DoD, Medicare) coverage.

Industry Context

The announcement is relevant to the pharmaceutical and oncology industries, particularly concerning treatments for cutaneous T-cell lymphoma (CTCL). The J-code assignment is expected to improve market access for LYMPHIR, potentially impacting the competitive landscape for CTCL therapies.

Comparison to Industry Standards

• LYMPHIR's approval and subsequent J-code assignment position it as a notable player in the CTCL treatment landscape, competing with other therapies such as brentuximab vedotin (Adcetris) and mogamulizumab (Poteligeo).
• The $400 million market estimate suggests a significant commercial opportunity, comparable to other niche oncology markets.
• The safety profile of LYMPHIR, including the boxed warning for CLS, is consistent with other targeted therapies that carry risks of serious adverse events.

Stakeholder Impact

• Patients with CTCL may benefit from improved access to LYMPHIR.
• Healthcare providers will have a clearer billing process for LYMPHIR.
• Citius Pharmaceuticals and Citius Oncology shareholders may see increased revenue from LYMPHIR sales.
• Payers (insurance companies) will need to incorporate the new J-code into their systems.

Next Steps

• Healthcare providers will begin using the permanent J-code (J9161) when submitting claims for LYMPHIR, effective April 1, 2025.
• Citius will continue to work on commercializing LYMPHIR and advancing its other product candidates.

Key Dates

Keywords

LYMPHIR, J-code, cutaneous T-cell lymphoma, CTCL, reimbursement, Citius Oncology, Citius Pharmaceuticals, denileukin diftitox-cxdl, FDA approval, oncology